Tumor Microenvironment and Progression to Invasion after a Diagnosis of Ductal Carcinoma In situ
Abstract
Ductal carcinoma in situ (DCIS) makes up 18% of all new breast cancer diagnoses, and is considered a precursor to invasive breast cancer even though the majority of cases almost 70% may never progress to invasive disease. Markers that identify which patients are most likely to experience progression are critically needed so that fewer patients are over-treated. This study is evaluating two novel tumor markers that may indicate greater risk of tumor progression based on recent work that suggests that stromal syndecan-1 expression induces an extracellular matrix with an aligned collagen fiber architecture, and that this collagen alignment in turn facilitates malignant cell invasion. We are using archived tumor tissue from 267 cases of DCIS of the breast to evaluate syndecan-1 expression and collagen alignment. These DCIS cases, diagnosed between 1995 and 1999, have been followed for breast cancer outcomes; to-date, 12.5% of cases have experienced a second breast cancer diagnosis. Analysis of syndecan-1 expression and collagen alignment patterns is on-going. Data analysis will ensue upon completion of tumor markers. No scientific knowledge has yet been produced.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2012
- Accession Number
- ADA561909
Entities
People
- Amy Trentham-dietz
- Patricia J. Keely
Organizations
- University of Wisconsin–Madison